Assessment of the classical MDR phenotype in epithelial ovarian carcinoma using primary cultures: A feasibility study

被引:0
|
作者
Coley, HM
Sargent, JM [1 ]
Williamson, CJ
Titley, J
Scheper, RJ
Gregson, SE
Elgie, AW
Lewandowicz, GM
Taylor, CG
机构
[1] Pembury Hosp, Pembury TN2 4QJ, Kent, England
[2] Inst Canc Res, CRC, Ctr Canc Therapeut, Sutton SM2 5NG, Surrey, England
[3] Free Univ Amsterdam Hosp, Dept Pathol, NL-1007 MB Amsterdam, Netherlands
关键词
MDR; ovarian cancer; P-glycoprotein; chemosensitivity; drug modulation;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This in vitro feasibility study has assessed a number of techniques and their applicability when looking at the role of multidrug resistance (MDR) in solid tumours. Fresh tumour material was obtained from 34 patients, (11 previously treated, 23 untreated) with ovarian adenocarcinoma. Doxorubicin sensitivity was measured using the MTT assay +/- the cyclosporins, Pgp expression was assessed by immunocytochemistry with the MRK-16 MoAb and flow cytometry was used to assess intracellular drug accumulation +/- PSC 833. 85% of samples showed some evidence of modest chemosensitisation by the cyclosporins (median 1.74-fold). We saw a marked variation in the number of Pgp positive cells between patients (1-87%, median 31%). 63% of samples tested showed an enhancement of DNR accumulation in the presence of PSC 833, with a median increase of 7% (sample range 0-29%). The present study highlights some of the technical difficulties encountered when working with fresh tumour material ex vivo. We conclude that screening of patients for their suitability to enter clinical trials incorporating MDR modulating agents is technically demanding, but feasible.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 50 条
  • [41] A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A Gynecologic Oncology Group study
    Martin, Lainie P.
    Sill, Michael
    Shahin, Mark S.
    Powell, Matthew
    DiSilvestro, Paul
    Landrum, Lisa M.
    Gaillard, Stephanie L.
    Goodheart, Michael J.
    Hoffman, James
    Schilder, Russell J.
    GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 526 - 530
  • [42] A PHASE-II STUDY OF CARBOPLATIN AND HEXAMETHYLMELAMINE AS INDUCTION CHEMOTHERAPY IN ADVANCED EPITHELIAL OVARIAN-CARCINOMA
    KRISTENSEN, GB
    BAEKELANDT, M
    VERGOTE, IB
    TROPE, C
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (11) : 1778 - 1780
  • [43] Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma - A proposal for essential sites for lymph node biopsy
    Onda, T
    Yoshikawa, H
    Yokota, H
    Yasugi, T
    Taketani, Y
    CANCER, 1996, 78 (04) : 803 - 808
  • [44] Acceptability and Feasibility of Early Palliative Care Among Women with Advanced Epithelial Ovarian Cancer: A Randomized Controlled Pilot Study
    Cusimano, Maria C.
    Sajewycz, Katrina
    Harle, Ingrid
    Giroux, Janet
    Hanna, Tracie
    Willing, Stephanie
    Martin, Vickie
    Francis, Julie-Ann
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2021, 43 (06) : 707 - 715
  • [45] A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study
    Gold, Michael A.
    Brady, William E.
    Lankes, Heather A.
    Rose, Peter G.
    Kelley, Joseph L.
    De Geest, Koen
    Crispens, Marta A.
    Resnick, Kimberly E.
    Howell, Stephen B.
    GYNECOLOGIC ONCOLOGY, 2012, 125 (03) : 635 - 639
  • [46] Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records
    Lim, A. W. W.
    Mesher, D.
    Gentry-Maharaj, A.
    Balogun, N.
    Widschwendter, M.
    Jacobs, I.
    Sasieni, P.
    Menon, U.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2016, 123 (06) : 1012 - 1020
  • [47] Accuracy of Pretreatment Ultrasonography Assessment of Intra-Abdominal Spread in Epithelial Ovarian Cancer: A Prospective Study
    Tomasinska, Agnieszka
    Stukan, Maciej
    Badocha, Michal
    Myszewska, Aleksandra
    DIAGNOSTICS, 2021, 11 (09)
  • [48] The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma
    Al-Niaimi, Ahmed
    Dickson, Elizabeth L.
    Albertin, Cassandra
    Karnowski, Jennifer
    Niemi, Cassandra
    Spencer, Ryan
    Shahzad, Mian M. K.
    Uppal, Shitanshu
    Saha, Sandeep
    Rice, Laurel
    Mc Nally, Amy
    GYNECOLOGIC ONCOLOGY, 2016, 143 (03) : 521 - 525
  • [49] Impact of uterus-preserving surgery on Stage I primary mucinous epithelial ovarian carcinoma: A multi-institutional study with propensity score-weighted analysis
    Yoshihara, Masato
    Kajiyama, Hiroaki
    Tamauchi, Satoshi
    Iyoshi, Shohei
    Yokoi, Akira
    Suzuki, Shiro
    Kawai, Michiyasu
    Nagasaka, Tetsuro
    Takahashi, Kunihiko
    Matsui, Shigeyuki
    Kikkawa, Fumitaka
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2020, 150 (02) : 177 - 183
  • [50] A FEASIBILITY STUDY OF CISPLATIN ADMINISTRATION WITH LOW-VOLUME HYDRATION AND GLUTATHIONE PROTECTION IN THE TREATMENT OF OVARIAN-CARCINOMA
    BOHM, S
    SPATTI, GB
    DIRE, F
    ORIANA, S
    PILOTTI, S
    TEDESCHI, M
    TOGNELLA, S
    ZUNINO, F
    ANTICANCER RESEARCH, 1991, 11 (04) : 1613 - 1616